Bianca Weinstock-Guttman, EAN 2020 – CHORDS Study in RRMS With Suboptimal Prior Response to DMTs
Bianca Weinstock-Guttman (Jacobs School of Medicine and Biomedical Science, University of Buffalo, NY, USA) shares highlights of her presentation entitled: Effectiveness and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis who had a suboptimal response with prior disease-modifying therapy: 2-year findings from CHORDS (ClinicalTrials.gov Identifier: NCT02637856).
Questions
1. What are the potential advantages of ocrelizumab in patients with relapsing-remitting multiple sclerosis (MS) compared to other disease-modifying therapies? (0:05)
2. Could you tell us a little about the aims and design of the CHORDS study? (1:03)
3. What have been the 2-year efficacy and safety findings of this study, and what was the rate of malignancies in ocrelizumab-treated patients? (2:33)
4. Which patients are likely to benefit most from ocrelizumab and in whom is it contraindicated? (3:32)
5. What will be the next step in the clinical development of ocrelizumab? (4:25)
Speaker disclosure: Bianca Weinstock-Guttman reports receiving grants and/or personal fees from Biogen, EMD Serono, Novartis, Genenech, Malinckrodt, Abbvie and Celgene.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
